Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Rebetron (interferon alfa-2b / ribavirin)
- teriflunomide
Interactions between your drugs
interferon alfa-2b teriflunomide
Applies to: Rebetron (interferon alfa-2b / ribavirin), teriflunomide
Using teriflunomide together with interferon alfa-2b may increase the risk of serious infections. Rarely, these medications may also cause liver damage. Because teriflunomide can stay in your blood for a prolonged period after the last dose, interactions with other drugs may occur for some time even after you have stopped taking it. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You should also seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ribavirin food
Applies to: Rebetron (interferon alfa-2b / ribavirin)
Food can enhance the levels of ribavirin in your body. Ribavirin should be taken with food or just after eating. This will make it easier for your body to absorb the medication. Do not take it on an empty stomach. Swallow the tablet or capsule whole.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
AccessPak for HIV PEP Basic
AccessPak for HIV PEP Basic is used for HIV Infection, nonoccupational exposure, occupational ...
AccessPak for HIV PEP Expanded with Kaletra
AccessPak for HIV PEP Expanded with Kaletra is used for HIV Infection
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
AccessPak for HIV PEP Expanded with Viracept
AccessPak for HIV PEP Expanded with Viracept is used for HIV Infection
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Cimduo
Cimduo (lamivudine and tenofovir disoproxil fumarate) is used to treat HIV infection. Includes ...
Complera
Complera (emtricitabine, rilpivirine, and tenofovir) is used to treat HIV infection. Includes ...
Delstrigo
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) is a combination, oral, antiviral ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.